Curis, Inc. (NASDAQ:CRIS – Get Rating) – Equities research analysts at Cantor Fitzgerald issued their FY2022 earnings per share (EPS) estimates for Curis in a research note issued on Wednesday, September 21st. Cantor Fitzgerald analyst L. Watsek expects that the biotechnology company will earn ($0.69) per share for the year. Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Curis’ current full-year earnings is ($0.69) per share. Cantor Fitzgerald also issued estimates for Curis’ FY2023 earnings at ($0.80) EPS.
Curis (NASDAQ:CRIS – Get Rating) last posted its earnings results on Thursday, August 4th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.17). Curis had a negative return on equity of 68.41% and a negative net margin of 533.89%. During the same quarter in the prior year, the company earned ($0.12) EPS.
Curis Price Performance
Institutional Investors Weigh In On Curis
Institutional investors have recently made changes to their positions in the stock. Nisa Investment Advisors LLC increased its holdings in shares of Curis by 478.0% in the first quarter. Nisa Investment Advisors LLC now owns 61,200 shares of the biotechnology company’s stock worth $146,000 after purchasing an additional 50,612 shares during the period. Citigroup Inc. increased its holdings in shares of Curis by 101.3% in the fourth quarter. Citigroup Inc. now owns 467,705 shares of the biotechnology company’s stock worth $2,226,000 after purchasing an additional 235,390 shares during the period. M28 Capital Management LP increased its holdings in shares of Curis by 62.6% in the first quarter. M28 Capital Management LP now owns 4,243,293 shares of the biotechnology company’s stock worth $10,099,000 after purchasing an additional 1,634,442 shares during the period. Parallax Volatility Advisers L.P. bought a new position in shares of Curis in the fourth quarter worth $149,000. Finally, GSA Capital Partners LLP increased its stake in Curis by 53.9% in the first quarter. GSA Capital Partners LLP now owns 33,316 shares of the biotechnology company’s stock valued at $79,000 after acquiring an additional 11,668 shares during the last quarter. Hedge funds and other institutional investors own 47.21% of the company’s stock.
Curis Company Profile
Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation.
- Get a free copy of the StockNews.com research report on Curis (CRIS)
- The Institutions Hold On To Darden Restaurants International
- What Steelcase’s Earnings Say About the Return to the Office?
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Is The Golden Age Of Homebuilding Already Over?
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.